Anticoagulant therapy has become one of the cornerstones of care in reducing the risk of thrombotic events in patients with NVAF, DVT, and PE.
Treatment guidelines recommend anticoagulation treatment as first-line treatment for patients with NVAF, DVT, and PE.10,11
Anticoagulants can act in several ways, including:
Vitamin K antagonists (eg, warfarin)
Heparin and derivatives (eg, pentasaccharide fondaparinux)
Direct thrombin inhibitors
Direct factor Xa inhibitors
One anticoagulant mechanism that has been shown to protect patients against clot formation is factor Xa inhibition.
The Factor Xa Signaling Cascade12:
See clinical trials data for one factor Xa inhibitor
Patient Factors to Consider
Certain factors, such as comorbidities, age, concominant medications, and renal impairment, may increase the risk of bleeding whilst receiving anticoagulant therapy; therefore, it is critical to consider these factors before deciding on a treatment paradigm.